| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| ADC Therapeutics SA | Chief Legal Officer | Common Shares | 189K | $590K | $3.13 | Dec 6, 2024 | Direct |
| ANTARES PHARMA, INC. | EVP, General Counsel, Chief Compliance Officer and Secretary | Common Stock | 0 | $5.60 | May 24, 2022 | Direct | |
| ANTARES PHARMA, INC. | EVP, General Counsel, Chief Compliance Officer and Secretary | Stock Option (right to buy) | 0 | May 24, 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ADCT | ADC Therapeutics SA | Dec 6, 2024 | 1 | -$130K | 4 | Dec 9, 2024 | Chief Legal Officer |
| ADCT | ADC Therapeutics SA | Jan 2, 2024 | 0 | $0 | 3 | Jan 2, 2024 | Chief Legal Officer |
| ATRS | ANTARES PHARMA, INC. | May 24, 2022 | 10 | -$4.15M | 4 | May 26, 2022 | EVP, General Counsel, Chief Compliance Officer and Secretary |
| ATRS | ANTARES PHARMA, INC. | Mar 3, 2022 | 2 | -$51.8K | 4 | Mar 4, 2022 | EVP General Counsel, Secretary |
| ATRS | ANTARES PHARMA, INC. | Feb 16, 2022 | 2 | -$48.7K | 4 | Feb 18, 2022 | EVP General Counsel, Secretary |
| ATRS | ANTARES PHARMA, INC. | Jun 10, 2021 | 4 | $212K | 4 | Jun 14, 2021 | EVP General Counsel, Secretary |
| ATRS | ANTARES PHARMA, INC. | Jun 8, 2021 | 1 | -$70.2K | 4 | Jun 10, 2021 | EVP General Counsel, Secretary |